{
    "Clinical Trial ID": "NCT00146172",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Neratinib 40 mg",
        "Neratinb 40 mg qd",
        "INTERVENTION 2: ",
        "  Neratinib 80 mg",
        "Neratinib 80 mg qd"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Her2/neu or Her1/EGFR positive cancer",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
        "  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)",
        "Exclusion Criteria:",
        "  Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent of greater than 300 mg/m^2",
        "  Patients with significant cardiac risk factors",
        "  Active central nervous system metastasis"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Dose Limiting Toxicity (DLT)",
        "  DLT is defined as any neratinib-related nonhematologic grade 3 or any grade 4 adverse event (AE) according to the National Cancer Institute (NCI) common terminology criteria (CTC) for AEs version 3.0. DLTs were assessed from the first single dose to 14 days of continuous daily administration.",
        "  Time frame: From first dose date to day 14",
        "Results 1: ",
        "  Arm/Group Title: Neratinib 40 mg",
        "  Arm/Group Description: Neratinb 40 mg qd",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: Neratinib 80 mg",
        "  Arm/Group Description: Neratinib 80 mg qd",
        "  Overall Number of Participants Analyzed: 4",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/3 (100.00%)",
        "  Anaemia 1/3 (33.33%)",
        "  Cardio-respiratory arrest 0/3 (0.00%)",
        "  Tachycardia 1/3 (33.33%)",
        "  Papilloedema 0/3 (0.00%)",
        "  Photophobia 0/3 (0.00%)",
        "  Vitreous haemorrhage 0/3 (0.00%)",
        "  Abdominal distension 0/3 (0.00%)",
        "  Abdominal pain 0/3 (0.00%)",
        "  Ascites 0/3 (0.00%)",
        "  Diarrhoea 0/3 (0.00%)",
        "  Nausea 0/3 (0.00%)",
        "  Small intestinal obstruction 0/3 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/4 (25.00%)",
        "  Anaemia 0/4 (0.00%)",
        "  Cardio-respiratory arrest 0/4 (0.00%)",
        "  Tachycardia 0/4 (0.00%)",
        "  Papilloedema 0/4 (0.00%)",
        "  Photophobia 0/4 (0.00%)",
        "  Vitreous haemorrhage 0/4 (0.00%)",
        "  Abdominal distension 0/4 (0.00%)",
        "  Abdominal pain 0/4 (0.00%)",
        "  Ascites 0/4 (0.00%)",
        "  Diarrhoea 0/4 (0.00%)",
        "  Nausea 0/4 (0.00%)",
        "  Small intestinal obstruction 0/4 (0.00%)"
    ]
}